Search Results - "Farrington, Graham K."

Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier by Haqqani, Arsalan S, Delaney, Christie E, Brunette, Eric, Baumann, Ewa, Farrington, Graham K, Sisk, William, Eldredge, John, Ding, Wen, Tremblay, Tammy-Lynn, Stanimirovic, Danica B

“…Current methods for examining antibody trafficking are either non-quantitative such as immunocytochemistry or require antibody labeling with tracers. We have…”
Get full text

Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies by Stanimirovic, Danica, Kemmerich, Kristin, Haqqani, Arsalan S, Farrington, Graham K

“…The development and approval of antibody-based therapeutics have progressed rapidly over the past decade. However, poor blood-brain barrier (BBB) permeability…”
Get more information

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR by Michaelson, Jennifer S., Demarest, Stephen J., Miller, Brian, Amatucci, Aldo, Snyder, William B., Wu, Xiufeng, Huang, Flora, Phan, Samantha, Gao, Sharon, Doern, Adam, Farrington, Graham K., Lugovskoy, Alexey A., Joseph, Ingrid, Bailly, Veronique, Wang, Xin, Garber, Ellen, Browning, Jeff, Glaser, Scott M.

“…Bispecific antibodies (BsAbs) represent an emerging class of biologics that achieve dual targeting with a single agent. Recombinant DNA technologies have…”
Get full text

Formation of Virus-like Clusters Is an Intrinsic Property of the Tumor Necrosis Factor Family Member BAFF (B Cell Activating Factor) by Cachero, Teresa G, Schwartz, Ian M, Qian, Fang, Day, Eric S, Bossen, Claudia, Ingold, Karine, Tardivel, Aubry, Krushinskie, Dennis, Eldredge, John, Silvian, Laura, Lugovskoy, Alexey, Farrington, Graham K, Strauch, Kathy, Schneider, Pascal, Whitty, Adrian

“…The oligomeric state of BAFF (B cell activing factor), a tumor necrosis factor (TNF) family cytokine that plays a critical role in B cell development and…”
Get full text

A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics by Farrington, Graham K., Caram‐Salas, Nadia, Haqqani, Arsalan S., Brunette, Eric, Eldredge, John, Pepinsky, Blake, Antognetti, Giovanna, Baumann, Ewa, Ding, Wen, Garber, Ellen, Jiang, Susan, Delaney, Christie, Boileau, Eve, Sisk, William P., Stanimirovic, Danica B.

“…The blood‐brain barrier (BBB) prevents the access of therapeutic antibodies to central nervous system (CNS) targets. The engineering of bispecific antibodies…”
Get full text

A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics by Farrington, Graham K., Caram‐Salas, Nadia, Haqqani, Arsalan S., Brunette, Eric, Eldredge, John, Pepinsky, Blake, Antognetti, Giovanna, Baumann, Ewa, Ding, Wen, Garber, Ellen, Jiang, Susan, Delaney, Christie, Boileau, Eve, Sisk, William P., Stanimirovic, Danica B.

Get full text

Stoichiometry of LTβR Binding to LIGHT by Eldredge, John, Berkowitz, Steven, Corin, Alan F, Day, Eric S, Hayes, David, Meier, Werner, Strauch, Kathy, Zafari, Mohammad, Tadi, Madhavi, Farrington, Graham K

“…LTβR is a member of the TNF receptor family of proteins. It binds to two different cell surface ligands, LIGHT, a homotypic trimer, and LTα1β2, a heterotypic…”
Get full text

In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier by Caram-Salas, Nadia, Boileau, Eve, Farrington, Graham K, Garber, Ellen, Brunette, Eric, Abulrob, Abedelnasser, Stanimirovic, Danica

“…The neonatal Fc receptor, FcRn, mediates endocytic recycling pathway that prevents degradation of IgG and is expressed in most endothelial cells. The…”
Get more information

Stoichiometry of LTbetaR binding to LIGHT by Eldredge, John, Berkowitz, Steven, Corin, Alan F, Day, Eric S, Hayes, David, Meier, Werner, Strauch, Kathy, Zafari, Mohammad, Tadi, Madhavi, Farrington, Graham K

“…LTbetaR is a member of the TNF receptor family of proteins. It binds to two different cell surface ligands, LIGHT, a homotypic trimer, and LTalpha1beta2, a…”
Get full text

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR by Michaelson, Jennifer S, Demarest, Stephen J, Miller, Brian, Amatucci, Aldo, Snyder, William B, Wu, Xiufeng, Huang, Flora, Phan, Samantha, Gao, Sharon, Doern, Adam, Farrington, Graham K, Lugovskoy, Alexey, Joseph, Ingrid, Bailly, Veronique, Wang, Xin, Garber, Ellen, Browning, Jeff, Glaser, Scott M

“…Bispecific antibodies (BsAbs) represent an emerging class of biologics that achieve dual targeting with a single agent. Recombinant DNA technologies have…”
Get full text